Gary L. Stump
United States Military Academy
24 Papers
408 Citations
Gary L. Stump is an academic researcher from United States Military Academy. The author has contributed to research in topics: Hyperalgesia & Myocardial infarction. The author has an hindex of 13, co-authored 24 publications.
Chat about Author
Papers
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
B. Wesley Trotter,Kausik K. Nanda,Nathan R. Kett,Christopher P. Regan,Joseph J. Lynch,Gary L. Stump,Laszlo Kiss,Jixin Wang,Robert H. Spencer,Stefanie A. Kane,Rebecca B. White,Rena Zhang,Kenneth D. Anderson,Nigel J. Liverton,Charles J. Mcintyre,Douglas C. Beshore,George D. Hartman,Christopher J. Dinsmore +17 more
TL;DR: Structural modifications of isoquinolinone lead 1 afforded compounds with excellent potency, selectivity, and oral bioavailability that inhibited the Kv1.5 potassium channel and its associated cardiac potassium current, IKur.
96
NR2B-Selective N-Methyl-d-aspartate Antagonists: Synthesis and Evaluation of 5-Substituted Benzimidazoles
John A. McCauley,Cory R. Theberge,Joseph J. Romano,Susan B Billings,Kenneth D. Anderson,David A. Claremon,Roger M. Freidinger,Rodney A. Bednar,Scott D. Mosser,Stanley L. Gaul,Thomas M. Connolly,Cindra L. Condra,Menghang Xia,Michael E. Cunningham,Bohumil Bednar,Gary L. Stump,Joseph J. Lynch,Alison Macaulay,Keith A Wafford,Kenneth S. Koblan,Nigel J. Liverton +20 more
TL;DR: Two classes of 5-substituted benzimidazoles were identified as potent antagonists of the NR2B subtype of the N-methyl-d-aspartate (NMDA) receptor, and selected compounds show very good selectivity compared to other subtypes of the NMDA receptor.
63
Orally Efficacious NR2B-Selective NMDA Receptor Antagonists
Christopher F. Claiborne,John A. McCauley,Brian E. Libby,Neil Roy Curtis,Helen J. Diggle,Janusz Jozef Kulagowski,Stuart R. Michelson,Kenneth D. Anderson,David A. Claremon,Roger M. Freidinger,Rodney A. Bednar,Scott D. Mosser,Stanley L. Gaul,Thomas M. Connolly,Cindra L. Condra,Bohumil Bednar,Gary L. Stump,Joseph J. Lynch,Alison J. Macaulay,Keith A. Wafford,Kenneth S. Koblan,Nigel J. Liverton +21 more
TL;DR: A novel series of benzamidines was synthesized and shown to exhibit NR2B-subtype selective NMDA antagonist activity and is orally active in a carrageenan-induced rat hyperalgesia model of pain and shows no motor coordination side effects.
60
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Nigel J. Liverton,Rodney A. Bednar,Bohumil Bednar,John W. Butcher,Christopher F. Claiborne,David A. Claremon,Michael E. Cunningham,Anthony G. DiLella,Stanley L. Gaul,Brian E. Libby,Elizabeth A. Lyle,Joseph J. Lynch,John A. McCauley,Scott D. Mosser,Kevin Nguyen,Gary L. Stump,Hong Sun,Hao Wang,James Yergey,Kenneth S. Koblan +19 more
TL;DR: In this article, a novel series of NR2B subtype selective N-methyl-d-aspartate (NMDA) antagonists was reported, which improved off-target activity profile and oral bioavailability in multiple species coupled with good brain penetration.
45
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Christopher P. Regan,Laszlo Kiss,Gary L. Stump,Charles J. Mcintyre,Douglas C. Beshore,Nigel J. Liverton,Christopher J. Dinsmore,Joseph J. Lynch +7 more
TL;DR: The demonstration of AF termination with TAEA and ISQ-1 in the dog heart failure model extends the profile of antiarrhythmic efficacy of Kv1.5 blockade.
37